A phase I clinical trial on intratumoral (IT) administration of ipilimumab (IPI) plus nivolumab (NIVO) followed by intracavitary (IC) administration of nivolumab in patients with recurrent glioblastoma

Activiteit: Talk or presentation at a conference

Periode2020 → …
EvenementstitelESMO Immuno-Oncology Virtual Congres
EvenementstypeConference